The daily business briefing: October 22, 2020
Purdue Pharma agrees to pay $8.3 billion opioid settlement, negotiators say coronavirus relief might be passed after election, and more

- 1. OxyContin-maker Purdue Pharma to pay $8.3 billion opioid-crisis settlement
- 2. Negotiators say coronavirus relief might be passed after election
- 3. Stock futures fall as concerns about coronavirus relief continue
- 4. AstraZeneca coronavirus vaccine trial volunteer dies in Brazil
- 5. Chipotle returns to sales growth but stock falls

A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
1. OxyContin-maker Purdue Pharma to pay $8.3 billion opioid-crisis settlement
Purdue Pharma, maker of the painkiller OxyContin, plans to plead guilty to three felony criminal charges as part of an $8.3 billion settlement over the role the company and its drug played in the opioid epidemic, the Justice Department announced Wednesday. The agreement also resolves civil charges against Purdue related to the opioid crisis, which has killed hundreds of thousands of people. Purdue admitted to lying to the Drug Enforcement Administration about its monitoring of physicians to prevent the diversion of OxyContin to illegal channels. The deal does not eliminate criminal liability of Purdue's owners, the Sackler family. Family members said they behaved "ethically and lawfully." Some state attorneys general criticized the deal by saying it let the Sacklers off too easy.
2. Negotiators say coronavirus relief might be passed after election
Treasury Secretary Steven Mnuchin and House Speaker Nancy Pelosi (D-Calif.) said Wednesday they have made more progress toward a deal on a new coronavirus relief package, but suggested it might not be passed until after Election Day. Mnuchin and Pelosi said they were narrowing their differences on a potential $2 trillion stimulus agreement but suggested there might not be a way to get enough lawmakers on board before Nov. 3. "I'm optimistic that there will be a bill. It's a question of, is it in time to pay the November rent, which is my goal, or is it going to be shortly thereafter and retroactive?" Pelosi said on MSNBC. Larry Kudlow, a top White House economic adviser, confirmed that finalizing the terms of a relief package in Congress' lame-duck session "could be a possibility."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. Stock futures fall as concerns about coronavirus relief continue
U.S. stock index futures fell slightly early Thursday as uncertainty about a new coronavirus relief deal continued. Futures for the Dow Jones Industrial Average, the S&P 500, and the Nasdaq were down by about 0.3 percent several hours before the opening bell. All three of the main U.S. indexes fell on Wednesday, giving back early gains. The Dow dropped by 0.4 percent, while the S&P 500 and the tech-heavy Nasdaq fell by 0.2 percent and 0.3 percent, respectively. The market struggles came despite word from House Speaker Nancy Pelosi's spokesman that she and Treasury Secretary Steven Mnuchin were "closer to being able to put pen to paper to write legislation" on a coronavirus relief bill. The announcement by top intelligence officials that Iran and Russia were trying to interfere in the U.S. election added to the headwinds.
4. AstraZeneca coronavirus vaccine trial volunteer dies in Brazil
A volunteer in a COVID-19 vaccine trail drug-maker AstraZeneca is conducting with the University of Oxford has died in Brazil, the South American nation's National Health Surveillance Agency said Wednesday. The agency said it was formally notified Monday. The cause of death was not released, but Ian Jones, a professor of virology at the University of Reading in the United Kingdom, said it probably wasn't vaccine-related. AztraZeneca said in a statement to NBC News that the trial would continue. "We cannot comment on individual cases in an ongoing trial of the Oxford vaccine as we adhere strictly to medical confidentiality and clinical trial regulations, but we can confirm that all required review processes have been followed," the statement said.
5. Chipotle returns to sales growth but stock falls
Chipotle Mexican Grill reported Wednesday a return to quarterly sales growth despite the summertime coronavirus surge. Chipotle reported earnings of $3.76 a share after adjusting for such costs as restructuring and restaurant closures, down from $3.47 a share in the same period last year. But revenue returned to growth, totaling $1.6 billion, up from $1.4 billion a year earlier. Same-store sales jumped by 8.3 percent, exceeding analysts' expectations of a 7.3 percent gain, according to FactSet. Online sales growth of 202.5 percent led the way. The company did not provide a forecast for the current quarter, however, citing "ongoing uncertainty surrounding the future impact of COVID-19." Shares fell by 5 percent in after-hours trading following the results, after rising 1 percent in regular trading.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Harold Maass is a contributing editor at TheWeek.com. He has been writing for The Week since the 2001 launch of the U.S. print edition. Harold has worked for a variety of news outlets, including The Miami Herald, Fox News, and ABC News. For several years, he wrote a daily round-up of financial news for The Week and Yahoo Finance. He lives in North Carolina with his wife and two sons.
-
Biden's first rodeo
cartoons
By The Week Staff Published
-
Biden's stumble
Cartoons
By The Week Staff Published
-
The daily gossip: Travis Kelce chats about Taylor Swift's Chiefs game visit, Hollywood writers thrilled with details of new contract as strike ends, and more
The daily gossip: September 27, 2023
By Brendan Morrow Published
-
The daily business briefing: September 27, 2023
Business Briefing The FTC accuses Amazon of running an illegal online monopoly, Biden visits auto workers on picket line, and more
By Harold Maass Published
-
The daily business briefing: September 26, 2023
Business Briefing Ford halts work at $3.5 billion electric-vehicle battery plant, Costco offers members basic health care services, and more
By Harold Maass Published
-
The daily business briefing: September 25, 2023
Business Briefing Hollywood writers reach deal that would end strike, Canadian autoworkers ratify a new contract with Ford, and more
By Harold Maass Published
-
China: a superpower’s slump
The Explainer After 40 years of explosive growth, China’s economy is now in deep distress — with no turnaround in sight
By The Week Staff Published
-
The daily business briefing: September 22, 2023
Business Briefing Rupert Murdoch steps down as Fox, News Corp. chair, Cisco to buy Splunk in $28 billion cash deal, and more
By Harold Maass Published
-
The daily business briefing: September 21, 2023
Business Briefing The Fed leaves rates unchanged, Biden cancels debts for University of Phoenix borrowers, and more
By Harold Maass Published
-
The daily business briefing: September 20, 2023
Business Briefing Disney says it will invest $60 billion in theme parks, Instacart shares rise in debut, and more
By Harold Maass Published
-
The daily business briefing: September 19, 2023
Business Briefing Instacart prices its shares at top of range in IPO, the UAW threatens to widen its strike, and more
By Harold Maass Published